Associate Professor in Bone Marrow Transplantation with the following clinical and research interests:
--Allogeneic transplantation for Acute and Chronic Leukemia;
--Autologous transplantation for lymphoma; Multiple Myeloma.
• Principle Investigator for the following investigator initiated protocols:
1. Clofarabine followed by haploidentical transplant using Fludarabine, Busulfan, and total body Irradiation with post-transplant cyclophosphamide for high-risk hematological malignancies including AML and MDS.
2. Phase I-II study of the synergistic effect of combination therapy with tyrosine kinase inhibitor and FISH oil for the treatment of chronic myeloid leukemia with stable molecular disease.
Clinical Research: Principal investigator (2017-present)
• bcr-abl PCR Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase
• Clofarabine followed HSCT using Fludarabine, Busulfan, and Total-Body Irradiation with Post-Transplant Cyclophosphamide for Nonremission AML
Associate Professor in Bone Marrow Transplantation with the following clinical and research interests:
--Allogeneic transplantation for Acute and Chronic Leukemia;
--Autologous transplantation for lymphoma; Multiple Myeloma.
• Principle Investigator for the following investigator initiated protocols:
1. Clofarabine followed by haploidentical transplant using Fludarabine, Busulfan, and total body Irradiation with post-transplant cyclophosphamide for high-risk hematological malignancies including AML and MDS.
2. Phase I-II study of the synergistic effect of combination therapy with tyrosine kinase inhibitor and FISH oil for the treatment of chronic myeloid leukemia with stable molecular disease.
Clinical Research: Principal investigator (2017-present)
• bcr-abl PCR Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase
• Clofarabine followed HSCT using Fludarabine, Busulfan, and Total-Body Irradiation with Post-Transplant Cyclophosphamide for Nonremission AML